Open Access
Issue
OCL
Volume 21, Number 3, May-June 2014
Article Number D309
Number of page(s) 5
Section Dossier: Vitamin D, vitamin or hormone? / La vitamine D, vitamine ou hormone ?
DOI https://doi.org/10.1051/ocl/2013056
Published online 29 April 2014
  • Abe E, Miyaura C, Sakagami H, et al. 1981. Differentiation of mouse myeloid leukemia cells induced by 1α,25-dihydroxyvitamin D3. Proc. Natl. Acad. Sci. USA 78: 4990-4994. [CrossRef] [Google Scholar]
  • Ananthakrishnan AN, Khalili H, Higuchi LM, et al. 2012. Higher predicted vitamin D status is associated with reduced risk of Crohn’s disease. Gastroenterology 142: 482-489. [CrossRef] [PubMed] [Google Scholar]
  • Bertolini DL, Araujo PR, Silva RN, Duarte AJ, Tzanno-Martins CB. 1999. Immunomodulatory effects of vitamin D analog KH1060 on an experimental skin transplantation model. Transplant. Proc. 31: 2998-2999. [CrossRef] [PubMed] [Google Scholar]
  • Björkhem I, Holmberg I. 1978. Assay and properties of a mitochondrial 25-hydroxylase active on vitamine D3. J. Biol. Chem. 253: 842-849. [PubMed] [Google Scholar]
  • Bouillon R, Carmeliet G, Verlinden L, et al. 2008. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr. Rev. 29: 726-776. [CrossRef] [PubMed] [Google Scholar]
  • Bouillon R, Eelen G, Verlinden L, Mathieu C, Carmeliet G, Verstuyf A. 2006. Vitamin D and cancer. J. Steroid. Biochem. Mol. Biol. 102: 156-162. [CrossRef] [PubMed] [Google Scholar]
  • Bouillon R, Okamura WH, Norman AW. 1995. Structure-function relationships in the vitamin D endocrine system. Endocrine Rev. 16: 200-257. [Google Scholar]
  • Cantorna MT, Humpal-Winter J, De Luca HF. 2000. In vivo regulation of interleukin-4 is one mechanism underlying the immunoregulatory effects of 1,25-dihydroxyvitamin D(3). Arch. Biochem. Biophys. 377: 135-138. [CrossRef] [PubMed] [Google Scholar]
  • Chen W, Chiang JY. 2003. Regulation of human sterol 27-hydroxylase gene (CYP27A1) by bile acids and hepatocyte nuclear factor 4alpha (HNF4alpha). Gene 313: 71-82. [CrossRef] [PubMed] [Google Scholar]
  • Cheng JB, Levine MA, Bell NH, Mangelsdorf DJ, Russell DW. 2004. Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. Proc. Natl. Acad. Sci. USA 101: 7711-7715. [CrossRef] [Google Scholar]
  • Cooke NC, Haddad JG. Vitamin D binding protein. In: Feldman D, Glorieux FH, Pike JW, eds. Vitamin D. San Diego, CA: Academic Press, 1997, pp. 87-101. [Google Scholar]
  • Cui Y, Rohan TE. 2006. Vitamin D, calcium and breast cancer risk: a review. Cancer Epidemiol. Biomarkers Prev. 15: 1427-1143. [CrossRef] [PubMed] [Google Scholar]
  • Davis CD, Hartmuller V, Freedman M, et al. 2007. Vitamin D and cancer: current dilemmas and future needs. Nutr. Rev. 65: S71-74. [CrossRef] [Google Scholar]
  • Deeb KK, Trump DL, Johnson CS. 2007. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat. Rev. Cancer 7: 684-700. [CrossRef] [PubMed] [Google Scholar]
  • Eloranta JJ, Kullak-Ublick GA. 2005. Coordinate transcriptional regulation of bile acid homeostasis and drug metabolism. Arch. Biochem. Biophys. 433: 397-412. [CrossRef] [PubMed] [Google Scholar]
  • Gallo S, Rodd C, Weiler H. 2013. Vitamin D supplementation during first 12 months of life – reply. JAMA 310: 853-854. [CrossRef] [Google Scholar]
  • Garabédian M. 2000. La 1,25dihydroxyvitamine D et son récepteur. Rev. Rhum. 11: 315-319. [Google Scholar]
  • Garland CF, Gorham ED, Mohr SB, et al. 2007. Vitamin D and prevention of breast cancer: pooled analysis. J. Steroid. Biochem. Mol. Biol. 103: 708-711. [CrossRef] [PubMed] [Google Scholar]
  • Gorham ED, et al. 2007. Optimal vitamin D status for colorectal cancer prevention: a quantitative meta-analysis. Am. J. Prev. Med. 32: 210-216. [CrossRef] [PubMed] [Google Scholar]
  • Gregori S, Casorati M, Amuchastegui S, Smiroldo S, Davalli AM, Adorini L. 2001. Regulatory T cells induced by 1α, 25-dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance. J. Immunol. 167: 1945-1953. [CrossRef] [PubMed] [Google Scholar]
  • Harjutsalo V, Sjoberg L, Tuomilehto J. 2008. Time trends in ẗhe incidence of type 1 diabetes in Finnish children: a cohort study. The Lancet 371: 1777-1782. [CrossRef] [Google Scholar]
  • Harris SS. 2005. Vitamin D in type I diabetes prevention. J. Nutr. 135: 323-325. [PubMed] [Google Scholar]
  • Holick MF, Garabédian, M. 2006. Vitamin D: Photobiology, Metabolism, Mechanism of action, and Clinical Applications in Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 6th edn. Washington: The American Society for Bone and Mineral Research, pp. 106-114. [Google Scholar]
  • Huang H, Porpodis K, Zarogoulidis P, et al. 2013. Vitamin D in asthma and future perspectives. Drug Des. Devel. Ther. 7: 1003-1013. [PubMed] [Google Scholar]
  • Hullett DA, Cantorna MT, Redaelli C, et al. 1998. Prolongation of allograft survival by 1,25-dihydroxyvitamin D3. Transplantation 66: 824-828. [CrossRef] [PubMed] [Google Scholar]
  • Johnsson C, Tufveson G. 1994. MC 1288 – a vitamin D analogue with immunosuppressive effects on heart and small bowel grafts. Transpl. Int. 7: 392-397. [PubMed] [Google Scholar]
  • Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP. 2007. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am. J. Clin. Nutr. 85: 1586-1591. [PubMed] [Google Scholar]
  • Leheste JR, Melsen F, Wellner M, et al. 2003. Hypocalcemia and osteopathy in mice with kidney-specific megalin gene defect. FASEB J. 17: 247-249. [PubMed] [Google Scholar]
  • Lemire J. 2000. 1,25-dihydroxyvitamin D3: a hormone with immunomodulatory properties. Z. Rheumatol. 1: 24-27. [CrossRef] [Google Scholar]
  • Madhock TC, De Luca HF. 1979. Characteristics of the rat liver microsomal enzyme system converting cholecalciferol into 25-hydroxycholecalciferol. Evidence for the participation of cytochrome p-450. Biochem. J. 184: 491-499. [PubMed] [Google Scholar]
  • Manolagas SC, Hustmyer FG, Yu XP. 1990. Immunomodulating properties of 1,25-dihydroxyvitamin D3. Kidney Int. 29: S9-S16. [PubMed] [Google Scholar]
  • Mathieu C, Waer M, Casteels K, Laureys J, Bouillon R. 1995. Prevention of type I diabetes in NOD mice by nonhypercalcemic doses of a new structural analog of 1,25-dihydroxyvitamin D3, KH1060. Endocrinology 136: 866-872. [PubMed] [Google Scholar]
  • Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. 2006. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 296: 2832-2838. [CrossRef] [PubMed] [Google Scholar]
  • Nagpal S, Na S, Rathnachalam R. 2005. Noncalcemic actions of vitamin D receptor ligands. Endocrine Rev. 26: 662-687. [CrossRef] [PubMed] [Google Scholar]
  • Nanzer AM, Chambers ES, Ryanna K, et al. 2013. Enhanced production of IL-17A in patients with severe asthma is inhibited by 1α, 25-dihydroxyvitamin D3 in a glucocorticoid-independent fashion. J. Allergy. Clin. Immunol. 132: 297-304. [CrossRef] [PubMed] [Google Scholar]
  • Nykjaer A, Dragun D, Walther D, et al. 1999. An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3. Cell 96: 507-515. [CrossRef] [PubMed] [Google Scholar]
  • Post SM, Duez H, Gervois PP, Staels B, Kuipers F, Princen HM. 2001. Fibrates suppress bile acid synthesis via peroxisome proliferator-activated receptor-alpha-mediated downregulation of cholesterol 7alpha-hydroxylase and sterol 27-hydroxylase expression. Arterioscler. Thromb. Vasc. Biol. 21: 1840-1845. [CrossRef] [PubMed] [Google Scholar]
  • Prosser DE, Jones G. 2004. Enzymes involved in the activation and inactivation of vitamin D. Trends Biochem. Sci. 29: 664-673. [CrossRef] [PubMed] [Google Scholar]
  • Quinn CM, Jessup W, Wong J, Kritharides L, Brown AJ. 2005. Expression and regulation of sterol 27-hydroxylase (CYP27A1) in human macrophages: a role for RXR and PPARgamma ligands. Biochem. J. 385: 823-830. [CrossRef] [PubMed] [Google Scholar]
  • Redaelli CA, Wagner M, Tien YH, et al. 2001. 1α, 25-Dihydroxycholecalciferol reduces rejection and improves survival in rat liver allografts. Hepatology 34: 926-934. [CrossRef] [PubMed] [Google Scholar]
  • Rizk-Rabin M, Zineb R, Zhor B, Michèle G, Jana P. 1994. Synthesis of and response to 1,25-dihydroxycholecalciferol by subpopulations of murine epidermalkeratinocytes: existence of a paracrine system for 1,25 dihydroxycholecalciferol. J. Cell. Physiol. 159: 131-141. [CrossRef] [PubMed] [Google Scholar]
  • Stamp TCB, Haddad G, Twigg CA. 1977. Comparison of oral 25-hydroxycholecalciferol, vitamin D, and ultraviolet light as determinants of circulating 25-hydroxyvitamin D. Lancet 1341-1343. [Google Scholar]
  • Van Etten E, Mathieu C. 2005. Immunoregulation by 1,25-dihydroxyvitamin D3: basic concepts. J. Steroid. Biochem. Mol. Biol. 97: 93-101. [CrossRef] [PubMed] [Google Scholar]
  • Wactawski-Wende J, Kotchen JM, Anderson GL, et al. 2006. Calcium plus vitamin D supplementation and the risk of colo-rectal cancer. N. Engl. J. Med. 354: 684-96. [CrossRef] [PubMed] [Google Scholar]
  • Webb AR, Holick MF. 1988. The role of sunlight in the cutaneous production of vitamin D3. Annu. Rev. Nutr. 8: 375-399. [CrossRef] [PubMed] [Google Scholar]
  • Windaus A, Linsert O. 1928. Vitamin D1. Ann. Chem. 465: 148. [CrossRef] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.